149 related articles for article (PubMed ID: 30463244)
1. Renal Cell Carcinoma Is Abrogated by p53 Stabilization through Transglutaminase 2 Inhibition.
Lee SH; Lee WK; Kim N; Kang JH; Kim KH; Kim SG; Lee JS; Lee S; Lee J; Joo J; Kwon WS; Rha SY; Kim SY
Cancers (Basel); 2018 Nov; 10(11):. PubMed ID: 30463244
[TBL] [Abstract][Full Text] [Related]
2. Renal cell carcinoma escapes death by p53 depletion through transglutaminase 2-chaperoned autophagy.
Kang JH; Lee JS; Hong D; Lee SH; Kim N; Lee WK; Sung TW; Gong YD; Kim SY
Cell Death Dis; 2016 Mar; 7(3):e2163. PubMed ID: 27031960
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel 1H-benzo[d]imidazole-4,7-dione based transglutaminase 2 inhibitors as p53 stabilizing anticancer agents in renal cell carcinoma.
Kim GR; Kang JH; Kim HJ; Im E; Bae J; Kwon WS; Rha SY; Chung HC; Cho EY; Kim SY; Kim YC
Bioorg Chem; 2024 Feb; 143():107061. PubMed ID: 38154386
[TBL] [Abstract][Full Text] [Related]
4. Allosteric inhibition site of transglutaminase 2 is unveiled in the N terminus.
Kim N; Kang JH; Lee WK; Kim SG; Lee JS; Lee SH; Park JB; Kim KH; Gong YD; Hwang KY; Kim SY
Amino Acids; 2018 Nov; 50(11):1583-1594. PubMed ID: 30105541
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Transglutaminase 2 but Not of MDM2 Has a Significant Therapeutic Effect on Renal Cell Carcinoma.
Kang JH; Lee SH; Lee JS; Oh SJ; Ha JS; Choi HJ; Kim SY
Cells; 2020 Jun; 9(6):. PubMed ID: 32560270
[TBL] [Abstract][Full Text] [Related]
6. Transglutaminase 2 inhibition found to induce p53 mediated apoptosis in renal cell carcinoma.
Ku BM; Kim DS; Kim KH; Yoo BC; Kim SH; Gong YD; Kim SY
FASEB J; 2013 Sep; 27(9):3487-95. PubMed ID: 23704086
[TBL] [Abstract][Full Text] [Related]
7. Transglutaminase 2 inhibitor abrogates renal cell carcinoma in xenograft models.
Ku BM; Kim SJ; Kim N; Hong D; Choi YB; Lee SH; Gong YD; Kim SY
J Cancer Res Clin Oncol; 2014 May; 140(5):757-67. PubMed ID: 24610445
[TBL] [Abstract][Full Text] [Related]
8. New Insights into Development of Transglutaminase 2 Inhibitors as Pharmaceutical Lead Compounds.
Kim SY
Med Sci (Basel); 2018 Oct; 6(4):. PubMed ID: 30297644
[TBL] [Abstract][Full Text] [Related]
9. Transglutaminase 2 Promotes Autophagy by LC3 Induction through p53 Depletion in Cancer Cell.
Kang JH; Lee SH; Cheong H; Lee CH; Kim SY
Biomol Ther (Seoul); 2019 Jan; 27(1):34-40. PubMed ID: 30231606
[TBL] [Abstract][Full Text] [Related]
10. Increased expression of transglutaminase 2 drives glycolytic metabolism in renal carcinoma cells.
Ku BM; Lee CH; Lee SH; Kim SY
Amino Acids; 2014 Jun; 46(6):1527-36. PubMed ID: 24643363
[TBL] [Abstract][Full Text] [Related]
11. Glucosamine is an effective chemo-sensitizer via transglutaminase 2 inhibition.
Kim DS; Park KS; Jeong KC; Lee BI; Lee CH; Kim SY
Cancer Lett; 2009 Jan; 273(2):243-9. PubMed ID: 18804908
[TBL] [Abstract][Full Text] [Related]
12. Depletion of cathepsin D by transglutaminase 2 through protein cross-linking promotes cell survival.
Kim SJ; Kim KH; Ahn ER; Yoo BC; Kim SY
Amino Acids; 2013 Jan; 44(1):73-80. PubMed ID: 21960143
[TBL] [Abstract][Full Text] [Related]
13. Preclinical evaluation of an
Wodtke R; Laube M; Hauser S; Meister S; Ludwig FA; Fischer S; Kopka K; Pietzsch J; Löser R
EJNMMI Radiopharm Chem; 2024 Jan; 9(1):1. PubMed ID: 38165538
[TBL] [Abstract][Full Text] [Related]
14. The role of apoptosis repressor with a CARD domain (ARC) in the therapeutic resistance of renal cell carcinoma (RCC): the crucial role of ARC in the inhibition of extrinsic and intrinsic apoptotic signalling.
Toth C; Funke S; Nitsche V; Liverts A; Zlachevska V; Gasis M; Wiek C; Hanenberg H; Mahotka C; Schirmacher P; Heikaus S
Cell Commun Signal; 2017 May; 15(1):16. PubMed ID: 28464919
[TBL] [Abstract][Full Text] [Related]
15. Synergistic roles of p53 and HIF1α in human renal cell carcinoma-cell apoptosis responding to the inhibition of mTOR and MDM2 signaling pathways.
Liu QJ; Shen HL; Lin J; Xu XH; Ji ZG; Han X; Shang DH; Yang PQ
Drug Des Devel Ther; 2016; 10():745-55. PubMed ID: 26937175
[TBL] [Abstract][Full Text] [Related]
16. Tropomyosin-1 promotes cancer cell apoptosis via the p53-mediated mitochondrial pathway in renal cell carcinoma.
Tang C; Wang J; Wei Q; Du YP; Qiu HP; Yang C; Hou YC
Oncol Lett; 2018 May; 15(5):7060-7068. PubMed ID: 29731872
[TBL] [Abstract][Full Text] [Related]
17. Novel suppressive effects of cardamonin on the activity and expression of transglutaminase-2 lead to blocking the migration and invasion of cancer cells.
Park MK; Jo SH; Lee HJ; Kang JH; Kim YR; Kim HJ; Lee EJ; Koh JY; Ahn KO; Jung KC; Oh SH; Kim SY; Lee CH
Life Sci; 2013 Feb; 92(2):154-60. PubMed ID: 23201552
[TBL] [Abstract][Full Text] [Related]
18. The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells.
Park KC; Heo JH; Jeon JY; Choi HJ; Jo AR; Kim SW; Kwon HJ; Hong SJ; Han KS
BMC Cancer; 2015 Jan; 15():19. PubMed ID: 25613585
[TBL] [Abstract][Full Text] [Related]
19. Prostate Transglutaminase (TGase-4) Induces Epithelial-to-Mesenchymal Transition in Prostate Cancer Cells.
Ablin RJ; Owen S; Jiang WG
Anticancer Res; 2017 Feb; 37(2):481-487. PubMed ID: 28179293
[TBL] [Abstract][Full Text] [Related]
20. Effects of tissue transglutaminase on beta -amyloid1-42-induced apoptosis.
Wakshlag JJ; Antonyak MA; Boehm JE; Boehm K; Cerione RA
Protein J; 2006 Jan; 25(1):83-94. PubMed ID: 16721663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
